Trial reportEuropean journal of nuclear medicine and molecular imaging2014
Sustained safety and efficacy of extended-shelf-life (90)Y glass microspheres: long-term follow-up in a 134-patient cohort.
Trial report in European journal of nuclear medicine and molecular imaging, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 24 citations in OpenAlex.
- The impact of microsphere deposition algorithm complexity on microdosimetry following Yttrium-90 radioembolization.Biomedical physics & engineering express · 2026Article
- Radioembolization of hepatocellular carcinoma withEuropean journal of nuclear medicine and molecular imaging · 2025Article
- MIDOS: a novel stochastic model towards a treatment planning system for microsphere dosimetry in liver tumors.European journal of nuclear medicine and molecular imaging · 2024Article
- Safety and Efficacy of Selective Internal Radionuclide Therapy withPharmaceuticals (Basel, Switzerland) · 2024Article
- Precision dosimetry in yttrium-90 radioembolization through CT imaging of radiopaque microspheres in a rabbit liver model.EJNMMI physics · 2022Article
- The number of microspheres in Y90 radioembolization directly affects normal tissue radiation exposure.European journal of nuclear medicine and molecular imaging · 2020Article
- Radioembolization Super Survivors: Extended Survival in Non-operative Hepatocellular Carcinoma.Cardiovascular and interventional radiology · 2018Article
- The dosimetric importance of the number of 90Y microspheres in liver transarterial radioembolization (TARE).European journal of nuclear medicine and molecular imaging · 2014Article
- Radioembolization of hepatic lesions from a radiobiology and dosimetric perspective.Frontiers in oncology · 2014Review
- Combination of 1In vivo (Athens, Greece)Article
- The development, commercialization, and clinical context of yttrium-90 radiolabeled resin and glass microspheres.Advances in radiation oncologyReview
- A review of 3D image-based dosimetry, technical considerations and emerging perspectives inJournal of diagnostic imaging in therapyArticle
Corrections and comments
- Commented on by
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo validate our initial pilot study and confirm sustained safety and tumor response of extended-shelf-life (90)Y glass microspheres. We hypothesized that for the same planned tissue dose, the increase in number of glass microspheres (decayed to the second week of their allowable shelf-life) administered for the same absorbed dose would result in better tumor distribution of the microspheres without causing additional adverse events.
methodsBetween June 2007 and January 2010, 134 patients underwent radioembolization with extended-shelf-life (90)Y glass microspheres; data from 84 new patients were combined with data from our 50-patient pilot study cohort. Baseline and follow-up imaging and laboratory data were obtained 1 and 3 months after therapy and every 3 months thereafter. Clinical and biochemical toxicities were prospectively captured and categorized according to the Common Terminology Criteria. Response in the index lesion was assessed using WHO and EASL guidelines.
resultsThe mean delivered radiation dose was 123 Gy to the target liver tissue. The mean increase in number of microspheres with this approach compared to standard (90)Y glass microsphere dosimetry was 103%, corresponding to an increase from 3.84 to 7.78 million microspheres. Clinical toxicities included fatigue (89 patients, 66%), abdominal pain (49 patients, 36.6%), and nausea/vomiting (25 patients, 18.7%). Grade 3/4 bilirubin toxicity was seen in three patients (2%). Two (1%) of the initial 50-patient cohort showed gastroduodenal ulcers; gastroduodenal ulcers were not seen in any of the subsequent 84 patients. According to WHO and EASL guidelines, response rates were 48% and 57%, respectively, and 21% demonstrated a complete EASL response.
conclusionThis study showed sustained safety and efficacy of extended-shelf-life (90)Y glass microspheres in a larger, 134-patient cohort. The increase in number of microspheres administered theoretically resulted in better tumor distribution of the microspheres without an increase in adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.